Equillium (NASDAQ:EQ) COO Christine Zedelmayer Sells 181,219 Shares of Stock

Equillium, Inc. (NASDAQ:EQ) COO Christine Zedelmayer sold 181,219 shares of the stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $2.00, for a total transaction of $362,438.00. Following the sale, the chief operating officer directly owned 62,586 shares in the company, valued at $125,172. This trade represents a 74.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Christine Zedelmayer also recently made the following trade(s):

• On Thursday, February 19th, Christine Zedelmayer sold 185,937 shares of Equillium stock. The stock was sold at an average price of $1.76, for a total transaction of $327,249.12.
• On Tuesday, December 23rd, Christine Zedelmayer sold 100,000 shares of Equillium stock. The stock was sold at an average price of $1.50, for a total value of $150,000.00.
• On Monday, December 15th, Christine Zedelmayer sold 11,900 shares of Equillium stock. The shares were sold at an average price of $1.31, for a total value of $15,589.00.
• On Friday, December 12th, Christine Zedelmayer sold 23,804 shares of Equillium stock. The shares were sold at an average price of $1.34, for a total value of $31,897.36.

Equillium Price Performance

Shares of EQ stock traded up $0.01 on Thursday, reaching $2.00. 38,345 shares of the stock were exchanged, compared to its average volume of 460,159. The stock has a market cap of $122.03 million, a PE ratio of -3.21 and a beta of 1.81. Equillium, Inc. has a one year low of $0.27 and a one year high of $2.35. The stock has a 50 day moving average price of $1.51 and a 200 day moving average price of $1.41.

Wall Street Analyst Weigh In

A number of research firms have issued reports on EQ. Wall Street Zen downgraded shares of Equillium from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Equillium in a research note on Monday, December 29th. Stifel Nicolaus initiated coverage on shares of Equillium in a report on Wednesday, February 25th. They issued a “buy” rating and a $5.00 price objective on the stock. Finally, Zacks Research raised shares of Equillium to a “hold” rating in a research note on Thursday, February 26th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $3.00.

Institutional Trading of Equillium

Large investors have recently bought and sold shares of the business. Virtu Financial LLC lifted its stake in Equillium by 133.4% in the third quarter. Virtu Financial LLC now owns 23,779 shares of the company’s stock valued at $34,000 after buying an additional 13,591 shares in the last quarter. State Street Corp increased its position in shares of Equillium by 13.0% during the fourth quarter. State Street Corp now owns 155,420 shares of the company’s stock worth $241,000 after acquiring an additional 17,900 shares in the last quarter. Persistent Asset Partners Ltd increased its position in shares of Equillium by 35.0% during the fourth quarter. Persistent Asset Partners Ltd now owns 93,123 shares of the company’s stock worth $144,000 after acquiring an additional 24,132 shares in the last quarter. Millennium Management LLC acquired a new stake in shares of Equillium during the third quarter worth $35,000. Finally, Geode Capital Management LLC raised its holdings in shares of Equillium by 11.1% during the fourth quarter. Geode Capital Management LLC now owns 345,310 shares of the company’s stock worth $535,000 after acquiring an additional 34,491 shares during the period. 27.05% of the stock is owned by institutional investors.

About Equillium

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.